Together these findings suggest the IL-33:ST2 axis does not play a central fibrogenic role in the lungs with therapeutic blockade of this pathway unlikely to surpass the current standard of care for IPF. The gene discussed is IL33; the disease is idiopathic pulmonary fibrosis.